[{"address1": "Clarence Thomas Building", "address2": "P.O. Box 4649 Road Town", "city": "Tortola", "zip": "VG1110", "country": "British Virgin Islands", "phone": "302 219 5556", "website": "https://www.portagebiotech.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors; PORT-6, a highly selective A2A receptor antagonist, which is in phase 1a for the treatment of solid tumors; PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; PORT-5, a VLP-STING to treat of solid tumors and is in preclinical trials; and PORT-7, a potent and selective antagonist of the adenosine A2B receptor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.", "fullTimeEmployees": 3, "companyOfficers": [{"maxAge": 1, "name": "Mr. Alexander  Pickett", "age": 36, "title": "CEO & Director", "yearBorn": 1988, "fiscalYear": 2025, "totalPay": 102870, "exercisedValue": 0, "unexercisedValue": 43200}, {"maxAge": 1, "name": "Ms. Eun-Jae  Park CPA", "age": 52, "title": "Chief Financial Officer", "yearBorn": 1972, "fiscalYear": 2025, "totalPay": 354601, "exercisedValue": 0, "unexercisedValue": 33600}, {"maxAge": 1, "name": "Dr. Robert A. Kramer Ph.D.", "age": 72, "title": "Chief Scientific Officer", "yearBorn": 1952, "fiscalYear": 2025, "totalPay": 119250, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Adam  Melero", "title": "Controller", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Peter  Molloy", "title": "Chief Executive Officer of Cyncado Therapeutics Inc.", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1767139200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 8.86, "open": 9.2811, "dayLow": 9.0585, "dayHigh": 9.7, "regularMarketPreviousClose": 8.86, "regularMarketOpen": 9.2811, "regularMarketDayLow": 9.0585, "regularMarketDayHigh": 9.7, "payoutRatio": 0.0, "beta": 0.599, "forwardPE": -17.51923, "volume": 15710, "regularMarketVolume": 15710, "averageVolume": 99106, "averageVolume10days": 29660, "averageDailyVolume10Day": 29660, "bid": 0.0, "ask": 8.81, "bidSize": 0, "askSize": 1, "marketCap": 20758228, "fiftyTwoWeekLow": 2.81, "fiftyTwoWeekHigh": 23.01, "fiftyDayAverage": 6.63468, "twoHundredDayAverage": 6.010965, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 18384246, "profitMargins": 0.0, "floatShares": 829851, "sharesOutstanding": 2278620, "sharesShort": 37398, "sharesShortPriorMonth": 93725, "sharesShortPreviousMonthDate": 1751241600, "dateShortInterest": 1753920000, "sharesPercentSharesOut": 0.0164, "heldPercentInsiders": 0.60566, "heldPercentInstitutions": 0.04168, "shortRatio": 1.85, "shortPercentOfFloat": 0.043, "impliedSharesOutstanding": 2278620, "bookValue": -0.074, "lastFiscalYearEnd": 1743379200, "nextFiscalYearEnd": 1774915200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -6767000, "trailingEps": -5.72, "forwardEps": -0.52, "lastSplitFactor": "1:20", "lastSplitDate": 1723680000, "enterpriseToEbitda": -2.49, "52WeekChange": 0.41900313, "SandP52WeekChange": 0.1513431, "quoteType": "EQUITY", "currentPrice": 9.11, "recommendationKey": "none", "totalCash": 1670000, "totalCashPerShare": 0.733, "ebitda": -7383000, "totalDebt": 0, "quickRatio": 1.529, "currentRatio": 2.023, "returnOnAssets": -0.92688006, "returnOnEquity": -5.41807, "freeCashflow": -3330125, "operatingCashflow": -5462000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "PRTG", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "exchange": "NCM", "longName": "Portage Biotech Inc.", "regularMarketChangePercent": 2.82167, "regularMarketPrice": 9.11, "corporateActions": [], "postMarketTime": 1755905850, "regularMarketTime": 1755892800, "messageBoardId": "finmb_233586353", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "shortName": "Portage Biotech Inc.", "marketState": "CLOSED", "postMarketPrice": 9.24, "postMarketChange": 0.13000011, "regularMarketChange": 0.25, "regularMarketDayRange": "9.0585 - 9.7", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 99106, "fiftyTwoWeekLowChange": 6.2999997, "fiftyTwoWeekLowChangePercent": 2.2419927, "fiftyTwoWeekRange": "2.81 - 23.01", "fiftyTwoWeekHighChange": -13.900001, "fiftyTwoWeekHighChangePercent": -0.6040852, "fiftyTwoWeekChangePercent": 41.900314, "dividendDate": 1591228800, "earningsTimestampStart": 1756324800, "earningsTimestampEnd": 1756324800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -5.72, "epsForward": -0.52, "fiftyDayAverageChange": 2.4753199, "fiftyDayAverageChangePercent": 0.37308806, "twoHundredDayAverageChange": 3.0990348, "twoHundredDayAverageChangePercent": 0.5155636, "priceToBook": -123.1081, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-02-25", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1009981800000, "postMarketChangePercent": 1.4270046, "displayName": "Portage Biotech", "trailingPegRatio": null, "__fetch_time": "2025-08-23"}]